Vaibhav Sahai
University of Michigan · University of Michigan Rogel Cancer Center · University of Michigan Comprehensive Cancer Center EDDOP
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Vaibhav Sahai as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07723534 · Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract CancersMidhun Malla · not yet recruiting · Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma · principal investigator
- Ph2NCT05988918 · Multicenter Trial of ESK981 in Patients With Select Solid TumorsUniversity of Michigan Rogel Cancer Center · active not recruiting · Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor · principal investigator
- Ph1/Ph2NCT05926206 · Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the PancreasUniversity of Michigan Rogel Cancer Center · withdrawn · Metastatic Pancreatic Adenocarcinoma · principal investigator
- Ph1NCT05411094 · Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerNational Cancer Institute (NCI) · active not recruiting · Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT04497038 · Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line TherapyUniversity of Michigan Rogel Cancer Center · terminated · Advanced Adult Hepatocellular Carcinoma · principal investigator
- Ph1/Ph2NCT04203160 · Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)University of Michigan Rogel Cancer Center · terminated · Biliary Tract Cancer · principal investigator
- Ph1/Ph2NCT03785873 · Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerUniversity of Michigan Rogel Cancer Center · completed · Biliary Tract Cancer · principal investigator
- Ph2NCT03639935 · Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyUniversity of Michigan Rogel Cancer Center · completed · Biliary Tract Cancer · principal investigator
- Ph2NCT03101566 · Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerUniversity of Michigan Rogel Cancer Center · completed · Biliary Tract Neoplasms · principal investigator
- Ph2NCT02181634 · Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With CholangiocarcinomaPrECOG, LLC. · completed · Cholangiocarcinoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting the RNA Exosome for Cancer TherapeuticsR01CA213214 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2019 to 2023 · $479,616 awarded in 2023Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · fiscal years 2012 to 2026Named on NCT05411094
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:50 UTC. The ranking covers the 200 most relevant of 30 PubMed records, and a shared surname and initials can bring in a namesake. All 30 on PubMed
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol · 20201,327 citationsRCR 56.9
- Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.J Clin Oncol · 2020451 citationsRCR 18.9
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.J Clin Oncol · 2020341 citationsRCR 14.0
- Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.Clin Cancer Res · 2014253 citationsRCR 6.4
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.J Clin Oncol · 2019165 citationsRCR 5.4
- Vibrotactile frequency discrimination in human hairy skin.J Neurophysiol · 2006124 citationsRCR 4.3
- Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.JAMA Oncol · 201899 citationsRCR 3.8
- Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.Invest New Drugs · 201898 citationsRCR 3.1
- An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.ESMO Open · 202489 citationsRCR 10.7
- 88 citationsRCR 3.8